Scribd
Upload
134 views1 page

Extravasation Hazard Table

The BC Cancer Extravasation Hazard Table categorizes various chemotherapy agents into four groups: vesicant, irritant, non-vesicant, and none, based on their potential to cause tissue damage upon extravasation. It includes specific drugs and notes on their hazard classification, with instructions to follow specific procedures for certain agents. The document also references the BC Cancer Systemic Therapy Policy III-20 for definitions and management guidelines related to extravasation.

Uploaded by

Rifai Arfan
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
134 views1 page

Extravasation Hazard Table

The BC Cancer Extravasation Hazard Table categorizes various chemotherapy agents into four groups: vesicant, irritant, non-vesicant, and none, based on their potential to cause tissue damage upon extravasation. It includes specific drugs and notes on their hazard classification, with instructions to follow specific procedures for certain agents. The document also references the BC Cancer Systemic Therapy Policy III-20 for definitions and management guidelines related to extravasation.

Uploaded by

Rifai Arfan
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

BC Cancer Extravasation Hazard Table

NONVESICANT
VESICANT
IRRITANT NONE
amsacrine arsenic trioxide aldesleukin lanreotide
busulfan azaCITIDine alemtuzumab leucovorin
carmustine bendamustine asparaginase leuprolide
DACTINomycin brentuximab vedotin† atezolizumab mesna (diluted)
DAUNOrubicin bortezomib avelumab methotrexate
DOXOrubicin CISplatin BCG methoxsalen
epirubicin dacarbazine bevacizumab mogamulizumab
IDArubicin DAUNOrubicin-cytarabine liposome bleomycin octreotide
melphalan DOCEtaxel blinatumomab oBINutuzumab
mitomycin DOXOrubicin pegylated liposomal buserelin nivolumab
streptozocin enfortumab vedotin† cabazitaxel pamidronate
vinBLAStine etoposide calaspargase pegol PANitumumab
vinCRIStine etoposide phosphate CARBOplatin pegaspargase
vindesine fluorouracil carfilzomib peginterferon alfa-2a
vinorelbine gemcitabine cemiplimab pembrolizumab
ifosfamide cetuximab pemetrexed
mesna (undiluted) cladribine PERTuzumab
mitoXANTRONE clodronate plerixafor
oxaliplatin* crisantaspase recombinant pralatrexate
PACLitaxel* cyclophosphamide ramucirumab
PACLitaxel-nab* cytarabine raltitrexed
polatuzumab vedotin† daratumumab riTUXimab
teniposide degarelix romiDEPsin
trastuzumab emtansine§ denosumab sacituzumab govitecan
treosulfan dexrazoxane sargramostim
dinutuximab siltuximab
durvalumab tebentafusp
eriBULin temsirolimus
filgrastim testosterone
fludarabine thiotepa
fulvestrant thyrotropin alfa
gemtuzumab ozogamicin‡ topotecan
goserelin trastuzumab
inotuzumab ozogamicin trastuzumab deruxtecan
ipilimumab zoledronic acid
irinotecan
isatuximab

*Follow specific procedures in Systemic Therapy Policy III-20 if extravasated.


†Contain potentially vesicant component but no reported cases of tissue necrosis or ulceration after extravasation
‡Some case reports of extravasation and injection site reactions or inflammation have been reported.
§Hazard classification is under review.

For definitions of different categories of extravasation hazard and the details on management of extravasation,
see BC Cancer Systemic Therapy Policy III-20 Prevention and Management of Extravasation of Chemotherapy.

BC Cancer Extravasation Hazard Table (Systemic Therapy Policy III-20)


Developed: 1 November 2014
Revised: 1 January 2025

You might also like